119 related articles for article (PubMed ID: 11038064)
21. Peripheral xenogeneic immunological response to encapsulated bovine adrenal chromaffin cells implanted within the sheep lumbar intrathecal space.
Kaplan FA; Krueger PM; Harvey J; Goddard MB
Transplantation; 1996 Apr; 61(8):1215-21. PubMed ID: 8610421
[TBL] [Abstract][Full Text] [Related]
22. Ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis.
Al-Chalabi A; Scheffler MD; Smith BN; Parton MJ; Cudkowicz ME; Andersen PM; Hayden DL; Hansen VK; Turner MR; Shaw CE; Leigh PN; Brown RH
Ann Neurol; 2003 Jul; 54(1):130-4. PubMed ID: 12838531
[TBL] [Abstract][Full Text] [Related]
23. Local and Systemic Humoral Response to Autologous Lineage-Negative Cells Intrathecal Administration in ALS Patients.
Baumert B; Sobuś A; Gołąb-Janowska M; Ulańczyk Z; Paczkowska E; Łuczkowska K; Zawiślak A; Milczarek S; Osękowska B; Meller A; Machowska-Sempruch K; Wełnicka A; Safranow K; Nowacki P; Machaliński B
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32041109
[TBL] [Abstract][Full Text] [Related]
24. Serum level of CNTF is elevated in patients with amyotrophic lateral sclerosis and correlates with site of disease onset.
Laaksovirta H; Soinila S; Hukkanen V; Röyttä M; Soilu-Hänninen M
Eur J Neurol; 2008 Apr; 15(4):355-9. PubMed ID: 18353124
[TBL] [Abstract][Full Text] [Related]
25. Protection of xenografts by a combination of immunoisolation and a single dose of anti-CD4 antibody.
Mckenzie AW; Georgiou HM; Zhan Y; Brady JL; Lew AM
Cell Transplant; 2001; 10(2):183-93. PubMed ID: 11332633
[TBL] [Abstract][Full Text] [Related]
26. Decrease in the ciliary neurotrophic factor of the spinal cord in amyotrophic lateral sclerosis.
Ono S; Imai T; Igarashi A; Shimizu N; Nakagawa H; Hu J
Eur Neurol; 1999; 42(3):163-8. PubMed ID: 10529543
[TBL] [Abstract][Full Text] [Related]
27. In-vivo delivery of therapeutic proteins by genetically-modified cells: comparison of organoids and human serum albumin alginate-coated beads.
Shinya E; Dervillez X; Edwards-Lévy F; Duret V; Brisson E; Ylisastigui L; Lévy MC; Cohen JH; Klatzmann D
Biomed Pharmacother; 1999 Dec; 53(10):471-83. PubMed ID: 10665341
[TBL] [Abstract][Full Text] [Related]
28. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
[TBL] [Abstract][Full Text] [Related]
29. Microencapsulated ciliary neurotrophic factor: physical properties and biological activities.
Maysinger D; Krieglstein K; Filipovic-Grcic J; Sendtner M; Unsicker K; Richardson P
Exp Neurol; 1996 Apr; 138(2):177-88. PubMed ID: 8620916
[TBL] [Abstract][Full Text] [Related]
30. In vivo recognition by the host adaptive immune system of microencapsulated xenogeneic cells.
Jones KS; Sefton MV; Gorczynski RM
Transplantation; 2004 Nov; 78(10):1454-62. PubMed ID: 15599309
[TBL] [Abstract][Full Text] [Related]
31. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group.
Neurology; 1996 May; 46(5):1244-9. PubMed ID: 8628460
[TBL] [Abstract][Full Text] [Related]
32. A characteristic ganglioside antibody pattern in the CSF of patients with amyotrophic lateral sclerosis.
Stevens A; Weller M; Wiethölter H
J Neurol Neurosurg Psychiatry; 1993 Apr; 56(4):361-4. PubMed ID: 7683329
[TBL] [Abstract][Full Text] [Related]
33. A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group.
Clin Neuropharmacol; 1995 Dec; 18(6):515-32. PubMed ID: 8681312
[TBL] [Abstract][Full Text] [Related]
34. Neuroprotective effects of encapsulated CNTF-producing cells in a rodent model of Huntington's disease are dependent on the proximity of the implant to the lesioned striatum.
Emerich DF; Winn SR
Cell Transplant; 2004; 13(3):253-9. PubMed ID: 15191163
[TBL] [Abstract][Full Text] [Related]
35. A gene therapy approach for the treatment of amyotrophic lateral sclerosis and Parkinson's disease.
Zurn AD; Tseng JL; Déglon N; Joseph JM; Aebischer P
Adv Pharmacol; 1998; 42():929-31. PubMed ID: 9328050
[No Abstract] [Full Text] [Related]
36. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis.
Ochs G; Penn RD; York M; Giess R; Beck M; Tonn J; Haigh J; Malta E; Traub M; Sendtner M; Toyka KV
Amyotroph Lateral Scler Other Motor Neuron Disord; 2000 Jun; 1(3):201-6. PubMed ID: 11464953
[TBL] [Abstract][Full Text] [Related]
37. Intraventricular implant of encapsulated CNTF-secreting fibroblasts ameliorates motor deficits in aged rats.
Emerich DF; Thanos CG; Sanberg PR
Curr Aging Sci; 2008 Jul; 1(2):105-11. PubMed ID: 20021379
[TBL] [Abstract][Full Text] [Related]
38. Intracompartmental delivery of CNTF as therapy for Huntington's disease and retinitis pigmentosa.
Emerich DF; Thanos CG
Curr Gene Ther; 2006 Feb; 6(1):147-59. PubMed ID: 16475952
[TBL] [Abstract][Full Text] [Related]
39. The immunomodulatory effects of human mesenchymal stem cells on peripheral blood mononuclear cells in ALS patients.
Kwon MS; Noh MY; Oh KW; Cho KA; Kang BY; Kim KS; Kim YS; Kim SH
J Neurochem; 2014 Oct; 131(2):206-18. PubMed ID: 24995608
[TBL] [Abstract][Full Text] [Related]
40. Cerebrospinal fluid and serum antibodies against neurofilaments in patients with amyotrophic lateral sclerosis.
Fialová L; Svarcová J; Bartos A; Ridzon P; Malbohan I; Keller O; Rusina R
Eur J Neurol; 2010 Apr; 17(4):562-6. PubMed ID: 19968709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
